Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2022-03-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the release of pledged shares by its controlling shareholder. It details the number of shares released from pledge, the proportion of shares involved, and confirms that the procedures have been completed with the securities registration and settlement company. The document is an announcement about a change in the status of pledged shares, which relates to shareholding and capital structure but does not report financial results or detailed financial data. It is not a full financial report, earnings release, or management discussion. It fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about share pledge status and does not fit more specific categories like Share Issue/Capital Change (SHA) or Director's Dealing (DIRS). The document length is short (1756 characters), and it is a standalone announcement, not a report publication or certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-03-24 Chinese
关于JK07美国临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the progress of a clinical trial for a drug (JK07) conducted by a subsidiary in the US. It provides detailed information about the FDA approval for a new clinical trial indication, preliminary clinical trial data, and background on the drug's development. The document is relatively short (1554 characters) and is an update on clinical trial progress rather than a financial report or regulatory filing. It does not contain financial statements, management discussion, or governance information. It is not an earnings release, annual report, or any form of financial or governance report. It is a regulatory announcement about clinical trial progress, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-03-07 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of its share repurchase program. It details the board meetings approving the repurchase plans, the amounts and prices involved, and the actual shares repurchased up to a certain date. The document includes compliance with relevant laws and stock exchange regulations about share buybacks. It does not contain financial statements or earnings data but focuses on the company's own shares repurchase activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is 2182 characters, which is consistent with an announcement rather than a full report.
2022-03-01 Chinese
关于SAL0114片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the approval of a clinical trial for a drug (SAL0114). It is a regulatory announcement about receiving a clinical trial approval notice from the National Medical Products Administration. The document does not contain financial data, earnings, or detailed reports but is a formal disclosure of a regulatory event related to drug development. It is not an annual report, earnings release, or any financial filing. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-02-25 Chinese
关于SAL0114片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a clinical trial for a drug (SAL0114). It is a regulatory announcement about a clinical trial approval from the National Medical Products Administration. The document does not contain financial statements, earnings data, or detailed financial analysis. It is not a report, but an announcement of a regulatory event related to drug development. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-16 Chinese
关于高级管理人员退休离任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation and retirement of a senior management personnel, specifically the vice general manager of the company. It details the resignation, effective date, and related compliance with regulatory guidelines. There is no financial data, report, or presentation included. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-02-06 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.